Sign in

Brian Lian

President and Chief Executive Officer at Viking Therapeutics
Board
Since September 2012
Age
58 years
Education
Holds an MBA in accounting and finance from Indiana University, an MS and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College.
Tenure
Has served as President and CEO of VKTX since its inception in September 2012.

Also at Viking Therapeutics

GZ
Greg Zante
Chief Financial Officer
MM
Marianne Mancini
Chief Operating Officer

About

Brian Lian, Ph.D., has an extensive academic background that includes degrees in chemistry and finance, providing him with a solid foundation in both scientific research and financial analysis.

He began his career in biotechnology as a research scientist at firms such as Amgen and Microcide Pharmaceuticals before transitioning into financial services where he held senior roles at institutions including CIBC World Markets, The Agave Group, Global Hunter Securities, and SunTrust Robinson Humphrey.

Since September 2012, he has served as President and CEO of VKTX, leading the company with over 15 years of experience in both biotechnology and financial services. His role has been complemented by board participation at Seelos Therapeutics, further demonstrating his broad expertise in the industry.

$VKTX Performance Under Brian Lian

Past Roles

OrganizationRoleDate RangeDetails
SunTrust Robinson Humphrey Managing Director and Senior Research Analyst 2012–2013 Covered small and mid-cap biotechnology companies in diabetes, oncology, infectious disease, and neurology
Global Hunter Securities Managing Director and Senior Research Analyst 2011–2012 N/A
The Agave Group, LLC Senior Healthcare Analyst 2008–2011 Registered investment advisor
CIBC World Markets Executive Director and Senior Biotechnology Analyst 2006–2008 N/A
Amgen Research Scientist in small molecule drug discovery N/A N/A
Microcide Pharmaceuticals Research Scientist N/A N/A

External Roles

OrganizationRoleDate RangeDetails
Seelos Therapeutics, Inc. Board of Directors Since January 2019 N/A

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary $615,000AnnualSubject to annual review with potential increases but no decreases
Non-Equity Incentive Plan Compensation $372,100AnnualNo detailed performance metrics or targets provided
Stock Option Awards 600,000 shares @ $8.5225% vest annually over 4 yearsExercisable until January 3, 2033; granted on January 3, 2023
RSU Awards 266,667 sharesVest one-third each year over 3 yearsContinuous service required; granted on January 3, 2023

Performance Compensation

Data from  FY 2023

PRSU Awards

MetricValueAdditional Details
Grant Date January 3, 2023Award granted on this date
Target Shares 665,000 sharesPerformance-based award with target share quantity
Performance Goals 100% vesting for 3 milestones; 133.3% vesting for 4 milestonesVesting over a 4-year period based on achievement of company milestones
Vesting Schedule Based on milestone completion over 4 yearsMilestone achievements determine vesting proportions
Forfeiture Condition Unvested shares forfeited if not vested by January 3, 2027Ensures timely performance milestone completion
Grant Date Fair Value $5,665,800Fair value assigned at the grant date